Incretin Atlas › Trials › Retatrutide phase 2 (obesity)
Retatrutide phase 2 (obesity)
Retatrutide · obesity
Design
- Molecule(s)
- Retatrutide
- Population
- obesity
- Phase
- 2
- Participants
- 338
- Duration
- 48 weeks
- Registry
- NCT04881760
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| retatrutide 12 mg | obesity | 48 | 338 | −24.2 % vs −2.1 % Δ −22.1 pp | — | — | 16.0 vs 0.0 | — | 45.0 vs 11.0 | 19.0 vs 1.0 | 3.0 vs 4.0 | — | verified |
| retatrutide 8 mg (start 4 mg) | obesity | 48 | 338 | −23.9 % vs −2.1 % Δ −21.8 pp | — | — | 6.0 vs 0.0 | — | 60.0 vs 11.0 | 26.0 vs 1.0 | 6.0 vs 4.0 | — | verified |
| retatrutide 4 mg (start 4 mg) | obesity | 48 | 338 | −17.8 % vs −2.1 % Δ −15.7 pp | — | — | 9.0 vs 0.0 | — | 36.0 vs 11.0 | 12.0 vs 1.0 | 6.0 vs 4.0 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (15)
- retatrutide 12 mg · ae_dc · Table 3, AEs leading to discontinuation
Any event 0 5 (7) 2 (6) 3 (9) 5 (14) 2 (6) 10 (16) 27 (8)
- retatrutide 12 mg · nausea · Table 3
Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
- retatrutide 12 mg · vomiting · Table 3
Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
- retatrutide 12 mg · sae · Table 3
Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
- retatrutide 12 mg · weight_eff · Results, Changes in Body Weight
−24.2% in the 12-mg group with an initial dose of 2 mg
- retatrutide 8 mg (start 4 mg) · ae_dc · Table 3
8 mg (initial 4 mg): 2 (6%)
- retatrutide 8 mg (start 4 mg) · nausea · Table 3
Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
- retatrutide 8 mg (start 4 mg) · vomiting · Table 3
Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
- retatrutide 8 mg (start 4 mg) · sae · Table 3
Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
- retatrutide 8 mg (start 4 mg) · weight_eff · Results, Changes in Body Weight
−23.9% in the 8-mg group (initial dose 4 mg)
- retatrutide 4 mg (start 4 mg) · ae_dc · Table 3
4 mg (initial 4 mg): 3 (9%)
- retatrutide 4 mg (start 4 mg) · nausea · Table 3
Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
- retatrutide 4 mg (start 4 mg) · vomiting · Table 3
Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
- retatrutide 4 mg (start 4 mg) · sae · Table 3
Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
- retatrutide 4 mg (start 4 mg) · weight_eff · Results, Changes in Body Weight
−17.8% in the 4-mg group with an initial dose of 4 mg
Primary sources
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.
- Eli Lilly and Company. A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities. ClinicalTrials.gov identifier NCT04881760. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04881760
How to cite this page
Medical Adviser's Group. Incretin Atlas: Retatrutide phase 2 (obesity). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/retatrutide-phase-2-obesity/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.